World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia

@article{Tandon2008WorldPA,
  title={World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia},
  author={R. Tandon and R. Belmaker and W. Gattaz and J. L{\'o}pez-Ibor and A. Okasha and Bruce S. Singh and Dan J Stein and J. Oli{\'e} and W. Fleischhacker and H. Moeller},
  journal={Schizophrenia Research},
  year={2008},
  volume={100},
  pages={20-38}
}
Data from two major government-funded studies of comparative antipsychotic effectiveness in schizophrenia contradict the widely prevalent belief that the newer second-generation medications are vastly superior to the older first-generation drugs. This has caused uncertainty among patients, clinicians and policy-makers about the relative utility of first- and second- generation antipsychotic agents in its treatment. To reduce confusion and provide a contextual understanding of the new data, the… Expand
Antipsychotic treatment of schizophrenia: an update.
The primary objectives in the treatment of schizophrenia are to reduce the frequency and severity of psychotic exacerbation, ameliorate a broad range of symptoms, and improve functional capacity andExpand
Pharmacological Treatment of Schizophrenia : Antipsychotic Update and Guidance for Best Practice
The primary objectives in the treatment of schizophrenia are to reduce frequency and severity of psychotic exacerbation, ameliorate a broad range of symptoms, prevent relapses, and improve functionalExpand
Antipsychotics in Adults With Schizophrenia: Comparative Effectiveness of First-Generation Versus Second-Generation Medications
TLDR
Clear benefits of FGAs versus SGAs for treating schizophrenia remain inconclusive because of variation in assessing outcomes and lack of clinically important differences for most comparisons. Expand
Comparative Efficacy and Safety of First - and Second-Generation Antipsychotics in the Treatment of Schizophrenia: Facts and Fiction
TLDR
These agents are found to be minimally effective, however, against negative and cognitive symptoms that contribute to much of the disability associated with schizophrenic illness and do not substantially diminish the suicidality and social dysfunction associated with the illness. Expand
Antipsychotic Polypharmacy and Associated Phenomena in Patients with Schizophrenia: Rational or Irrational?
TLDR
Prescription patterns of psychotropic drugs, relevant associated factors with antipsychotic polypharmacy and their inter-relationships with associated phenomena such as long acting antipsychotics use, prescription of FGA and SGA medications within a tertiary psychiatric hospital setting in Singapore are examined. Expand
Drugs in development for the treatment of schizophrenia
  • R. Emsley
  • Medicine
  • Expert opinion on investigational drugs
  • 2009
TLDR
An up-to-date review of antipsychotic drugs currently in development, focusing on the findings to date for compounds that are presently in Phase III clinical trials, suggests several drugs in early development have great potential. Expand
Targets for treating the full spectrum of symptoms of schizophrenia
The overall outcome in schizophrenia is generally poor, despite the undisputed efficacy of antipsychotics in treating the acute symptoms of psychosis. There remains a subset of patients who areExpand
Clozapine as treatment of first choice in first psychotic episodes. What do we know?
TLDR
The aim of the paper is to review the current medical evidence about the use of clozapine as a first-line treatment for naive first episode psychosis patients and to suggest that the incidence and mortality of clazapine-induced agranulocytosis could be lower than previously estimated and all-cause mortality due to clozAPine is less than that associated to other antipsychotic drugs. Expand
Recent Advances in the Antipsychotic Treatment of Schizophrenia
The primary objectives in the treatment of schizophrenia are to reduce frequency and severity of psychotic exacerbation, ameliorate a broad range of symptoms, and improve functional capacity andExpand
Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents
TLDR
An update and critical review of the pharmacology and clinical profiles of current antipsychotic drugs and drugs acting on novel targets with potential to be therapeutic agents in the future is provided. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 135 REFERENCES
Comparative efficacy of antipsychotics in the treatment of schizophrenia: A critical assessment
TLDR
Data thus far do not support claims of differential efficacy among SGAs with the singular exception of clozapine possibly still being the gold standard of antipsychotic efficacy in otherwise treatment-refractory schizophrenia. Expand
Are there any differences in the efficacy among second generation antipsychotics in the treatment of schizophrenia and related disorders?
TLDR
The results indicate that first-line second-generation antipsychotics show comparable efficacy, and possible new studies should focus on long-term effects, including cost-effectiveness, quality of life, social functioning and service utilization. Expand
Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
TLDR
After 2 months of antipsychotic treatment, all groups had a small but significant improvement in neurocognition, and after 18 months of treatment, neurocognitive improvement was greater in the perphenazine group than in the olanzapine and risperidone groups. Expand
The Efficacy and Safety of Conventional and Atypical Antipsychotics in First-Episode Schizophrenia: A Review of the Literature
TLDR
Initial data reviewed here suggest that long-acting risperidone, the first atypical antipsychotic available in a long- acting formulation, could be a valuable addition to the armamentarium of pharmacologic treatment strategies for longterm treatment of first-episode schizophrenia. Expand
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
TLDR
Olanzapine was the most effective in terms of the rates of discontinuation, and the efficacy of the conventional antipsychotic agent perphenazine appeared similar to that of quetiapine, risperidone, and ziprasidone. Expand
Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials.
TLDR
It is confirmed that treatment-resistant schizophrenic patients have more favorable outcomes when treated with clozapine rather than a typical antipsychotic, as reflected by Brief Psychiatric Rating Scale total score, categorical response rate, Scale for the Assessment of Negative Symptoms score, Simpson-Angus Rating Scale score, and compliance rate. Expand
The European First Episode Schizophrenia Trial (EUFEST): Rationale and design of the trial
TLDR
The aim of the European First Episode Schizophrenia Trial (EUFEST) is to compare treatment with amisulpride, quetiapine, olanzapine and ziprasidone to a low dose of haloperidol in an unselected sample of first episode schizophrenia patients with minimal prior exposure to antipsychotics. Expand
Management of the Negative Symptoms of Schizophrenia
TLDR
A systematic review of pharmacological treatment for negative symptoms of schizophrenia, based on MEDLINE searches from 1995 to September 2002 to identify pertinent clinical trials, suggests the atypical antipsychotics should be preferred for the treatment of negative symptoms. Expand
Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia.
TLDR
Although the atypical antipsychotics have overcome EPS, other side effects such as weight gain and impaired glucose tolerance/lipid abnormalities have come to the fore, so the challenges are far from over. Expand
Conceptual and Methodological Issues in the Design of Clinical Trials of Antipsychotics for the Treatment of Schizophrenia
Schizophrenia is one of the most severe and disabling psychiatric disorders. Antipsychotic drugs offer considerable benefits in controlling symptoms and preventing relapse. The strategy for theExpand
...
1
2
3
4
5
...